Hepatocellular carcinoma with macrovascular invasion: Review and survival meta-analysis of initial local therapy using minimal prognostic criteria

医学 肝细胞癌 内科学 肿瘤科 免疫疗法 临床终点 总体生存率 临床试验 生存分析 治疗方式 荟萃分析 癌 梅德林 模式 完全响应 终点测定 治疗方式 肝细胞癌 存活率 外科 抗体疗法 随机对照试验
作者
Marta Fortuny,Antonio De Rosa,Ignacio Roca,Dan Ouchi,Elisaul Suárez,Andrea Cadiz,Mario Matute‐González,Andrew M. Moon,Jordi Rimola,Ferràn Torres,María Reig
出处
期刊:Hepatology [Lippincott Williams & Wilkins]
卷期号:84 (5): 1371-1380 被引量:6
标识
DOI:10.1097/hep.0000000000001630
摘要

BACKGROUND AND AIMS: Macrovascular invasion (MaVI) defines advanced-stage hepatocellular carcinoma (HCC) and typically mandates systemic therapy, yet some guidelines advocate surgery or locoregional approaches. We conducted a systematic review and meta-analysis of overall survival (OS) in HCC with MaVI treated with approaches other than systemic therapy, enforcing stringent inclusion criteria to exclude studies lacking a minimal prognostic dataset and to improve cohort comparability. APPROACH AND RESULTS: PRISMA-guided methods were used (CRD420251051847). PubMed was searched (January 2008 to November 2024). Eligible studies reported OS for HCC with MaVI and provided baseline performance status and liver function; studies without adequate prognostic information were excluded. Data on OS at 1, 2, 3, and 5 years were extracted, and heterogeneity was assessed. Seventy-three studies met criteria (104 treatment arms; 10,329 patients). Despite a rigorous identification process, substantial heterogeneity persisted for most modalities ( I2 >80%), precluding robust pooling. Transarterial radioembolization (TARE) monotherapy was the only treatment with low heterogeneity ( I2 =0%) and showed a pooled 1-year OS of 34% (95% CI: 20%-48%). Apparent advantages of sequential strategies likely reflected confounding by indication and immortal-time bias, as only patients who lived long enough and were sufficiently fit proceeded through the full sequence. Data completeness declined beyond 12 months (missing OS: 0% at 1 y; 17.3% at 2 y; 32.7% at 3 y; 70.2% at 5 y). CONCLUSIONS: In HCC with MaVI, 1-year OS is the most comparable endpoint across modalities. This analysis identifies TARE as the only consistently reproducible option, showing a 1-year survival of 34%. In contrast, surgery and sequential therapies remain confounded by substantial heterogeneity. Accordingly, stratified head-to-head trials comparing alternative modalities against immunotherapy are warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
汉堡包的应助被科研通管家采纳,获得10
刚刚
geold发布了新的文献求助20
刚刚
Orange的应助被科研通管家采纳,获得10
刚刚
酷波er的应助被科研通管家采纳,获得10
刚刚
慕青的应助被科研通管家采纳,获得10
刚刚
SciGPT的应助被科研通管家采纳,获得10
刚刚
天天快乐的应助被科研通管家采纳,获得10
1秒前
1秒前
小二郎的应助被ali采纳,获得10
1秒前
汉堡包的应助被羊翊婕采纳,获得10
1秒前
上官若男的应助被youyyuy采纳,获得30
1秒前
2秒前
超级初夏完成签到,获得积分10
2秒前
yinlao完成签到,获得积分0
2秒前
晨曦完成签到,获得积分10
2秒前
3秒前
大海123完成签到,获得积分10
3秒前
luxinling完成签到,获得积分10
3秒前
戴帽子完成签到,获得积分10
3秒前
笼画陌完成签到,获得积分10
3秒前
加速度完成签到,获得积分10
3秒前
CWJ发布了新的文献求助10
4秒前
4秒前
顾矜的应助被faker采纳,获得10
4秒前
体贴夏柳发布了新的文献求助10
4秒前
czx完成签到,获得积分10
4秒前
无奈的小虾米完成签到,获得积分10
4秒前
tianwu完成签到,获得积分10
5秒前
5秒前
HAHA发布了新的文献求助10
5秒前
5秒前
大个的应助被李llllll采纳,获得10
6秒前
小蘑菇的应助被吹球球8采纳,获得10
6秒前
ccss发布了新的文献求助10
7秒前
橘子完成签到 ,获得积分10
7秒前
晨曦完成签到,获得积分10
7秒前
7秒前
619026854完成签到,获得积分10
7秒前
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287